Call for free European Vaccine Research and Development Services
18 January 2011
Austria
The European Vaccine Initiative, as coordinator of TRANSVAC European Network of Vaccine Research and Development has launched a call for Vaccine Development Applications. In order to support and accelerate vaccine development in Europe, the TRANSVAC project is providing a vaccine development platform that may be accessed for free by European groups and has recently called for the first applications.
Europe has significant vaccine research and development expertise - the home of 60% of global vaccine R&D. Cooperation between research institutions in Europe is critical for maintenance of expertise/competencies as well as to ensure the future of vaccine development in Europe. Currently there is little cooperation between R&D groups, assay developers and vaccine producers.
The TRANSVAC project was initiated as a collaborative infrastructure project funded under the European Commission’s 7th Framework Programme offering a complimentary set of coordinated vaccine research and development facilities by leading European groups. TRANSVAC’s vaccine development facilities are not linked to any particular type of disease.
Through a peer-reviewed competitive process, European groups may apply to benefit from the expertise, reagents, and facilities of the TRANSVAC project.
TRANSVAC is offering its set of coordinated vaccine R&D facilities and services to selected external groups free of charge. They are not restricted to any disease in particular. Only European user groups (from EU Members states or Associated states) can apply and only to TRANSVAC service infrastructures outside their own country. Briefly, TRANSVAC’s services include:
Access to adjuvants: External groups can send antigens that will be returned formulated with the required adjuvants
Animal models: External groups can test their experimental vaccines/antigens in mouse, pig, and non-human primate models
Standards: External groups can receive standardized reagents for application in several commonly-used assays
Global analysis: External groups can send samples that will be analyzed using microarrays or deep sequencing platforms.
The call was launched in November 2010. The call will remain open for the duration of the project (until Sept 2013) or until all of the services have been exhausted. Application forms may be downloaded from the TRANSVAC website and once completed will be reviewed by the TRANSVAC Scientific Advisory Committee and User Selection Panel, before approval by the TRANSVAC Steering Committee. The selected projects will then be able to commence work within TRANSVAC from Spring 2011 and onwards.
More information:
www.transvac.org
Europe has significant vaccine research and development expertise - the home of 60% of global vaccine R&D. Cooperation between research institutions in Europe is critical for maintenance of expertise/competencies as well as to ensure the future of vaccine development in Europe. Currently there is little cooperation between R&D groups, assay developers and vaccine producers.
The TRANSVAC project was initiated as a collaborative infrastructure project funded under the European Commission’s 7th Framework Programme offering a complimentary set of coordinated vaccine research and development facilities by leading European groups. TRANSVAC’s vaccine development facilities are not linked to any particular type of disease.
Through a peer-reviewed competitive process, European groups may apply to benefit from the expertise, reagents, and facilities of the TRANSVAC project.
TRANSVAC is offering its set of coordinated vaccine R&D facilities and services to selected external groups free of charge. They are not restricted to any disease in particular. Only European user groups (from EU Members states or Associated states) can apply and only to TRANSVAC service infrastructures outside their own country. Briefly, TRANSVAC’s services include:
Access to adjuvants: External groups can send antigens that will be returned formulated with the required adjuvants
Animal models: External groups can test their experimental vaccines/antigens in mouse, pig, and non-human primate models
Standards: External groups can receive standardized reagents for application in several commonly-used assays
Global analysis: External groups can send samples that will be analyzed using microarrays or deep sequencing platforms.
The call was launched in November 2010. The call will remain open for the duration of the project (until Sept 2013) or until all of the services have been exhausted. Application forms may be downloaded from the TRANSVAC website and once completed will be reviewed by the TRANSVAC Scientific Advisory Committee and User Selection Panel, before approval by the TRANSVAC Steering Committee. The selected projects will then be able to commence work within TRANSVAC from Spring 2011 and onwards.
More information:
www.transvac.org
Keywords
Microbiology